Phase II trial of vorinostat in advanced melanoma

Investigational New Drugs

Volumn 32, Issue 3, 2014, Pages 526-534

  Haas, N B ^a   Quirt, I ^b   Hotte, S ^c   McWhirter, E ^c   Polintan, R ^b   Litwin, S ^d   Adams, P D ^e   McBryan, T ^e   Wang, L ^b   Martin, L P ^d   VonMehren, M ^d   Alpaugh, R K ^d   Zweibel, J ^f   Oza, A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f Clinical Trials Evaluation Program   (United States)

Author keywords

Angiogenesis; Chromatin associated proteins; Histone deacetylase inhibitor; Melanoma

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; CREATININE; FIBROBLAST GROWTH FACTOR; HISTONE; HISTONE H3; HISTONE H4; MACROH2A1.1 PROTEIN; MACROH2A1.2 PROTEIN; PROTEIN P52; UNCLASSIFIED DRUG; VASCULOTROPIN; VORINOSTAT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; MACROH2A HISTONE; PROTEIN P53; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CUTANEOUS MELANOMA; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE REDUCTION; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INTERNATIONAL NORMALIZED RATIO; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; UVEA MELANOMA; VASCULAR DISEASE; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MELANOMA; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLAST GROWTH FACTORS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MALE; MELANOMA; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904654496     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0066-9     Document Type: Article

References (29)

1. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nature reviews Cancer 11:726-734
2. Arts J, de Schepper S, Van Emelen K (2003) Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics. Curr Med Chem 10:2343-2350 (Pubitemid 37236391)
3. Marks P, Rifkind RA, Richon VM et al (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194-202 (Pubitemid 33741894)
4. Kelly WK, O'Connor OA, Marks PA (2002) Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 11:1695-1713 (Pubitemid 35469917)
5. Kim SH, Ahn S, Han JW et al (2004) Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 315(4):964-970 (Pubitemid 38249397)
6. Zhang XD, Gillespie SK, Borrow JM, Hersey P (2003) The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 66(8):1537-1545 (Pubitemid 38373344)
7. Klisovic DD, Katz SE, Effron D, Klisovic MI, Wickham J, Parthun MR, Guimond M, Marcucci G (2003) Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci 44(6):2390-2398 (Pubitemid 36618393)
8. Demary K, Wong L, Spanjaard RA et al (2001) Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett 163(1):103-107 (Pubitemid 32121835)
9. Yamamoto S, Yamano T, Tanaka M et al (2003) A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther 10(3):179-186 (Pubitemid 36348678)
10. Vo DD, Prins RM, Begley JL et al (2009) Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 69(22):8693-8699
11. Munster PN, Marchion D, Thomas S et al (2009) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 101(7):1044-1050
12. Kato Y, Salumbides BC, Wang XF et al (2007) Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 6(1):70-81 (Pubitemid 46206669)
13. Kelly WK, Richon VM, O'Connor O et al (2003) Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578-3588 (Pubitemid 37169221)
14. Zhang R, Liu ST, Chen W, Bonner M, Pehrson J, Yen TJ, Adams PD (2007) HP1 proteins are essential for a dynamic nuclear response that rescues the function of perturbed heterochromatin in primary human cells. Mol Cell Biol 27(3):949-962 (Pubitemid 46178114)
15. Zhang R, Adams PD (2007) Heterochromatin and its relationship to cell senescence and cancer therapy. Cell Cycle 6(7):784-789, Epub 2007 Apr 27. Review
16. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3(4):387-402 (Pubitemid 38340307)
17. Shen H, Liu Z, Strom SS, Spitz MR, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Ananthaswamy HN, Wei Q (2003) p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol 121(6):1510-1514 (Pubitemid 38005506)
18. Dumont P, Leu JI, 3rd Della Pietra AC, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33(3):357-365 (Pubitemid 36278852)
19. Streit M, Detmar M (2003) Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 22(20):3172-3179 (Pubitemid 36713769)
20. Gitay-Goren H, Halaban R, Neufeld G (1993) Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 190(3):702-708
21. Lazar-Molnar E, Hegyesi H, Toth S, Falus A (2000) Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine+ 12(6):547-554 (Pubitemid 30453481)
22. Dreau D, Foster M, Hogg M, Swiggett J, Holder WD, White RL (2000) Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma. Oncol Res 12(5):241-251
23. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N, Blacher S, Verdin E, Foidart JM, Nusgens BV, Castronovo V (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21(3):427-436 (Pubitemid 34123805)
24. Zgouras D, Becker U, Loitsch S, Stein J (2004) Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem Biophys Res Commun 316(3):693-697 (Pubitemid 38368008)
25. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7(4):437-443 (Pubitemid 32298546)
26. Response Evaluation Criteria in Solid Tumors (RECIST) Committee. JNCI 92(3):205-216, 2000
27. Atkins MB, Kunkel L, Sznol M, Rosenberg SA (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(Suppl 1):S11-S14
28. Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707-714
29. Hou P, Liu D, Dong J, Xing M (2012) The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle 11(2):286-295